Jami Rubin

In a report published on Friday, Goldman Sachs analyst Jami Rubin Downgraded Allergan (NYSE: AGN) from Buy to Neutral and maintained a $110 price target on the company. In the report, Goldman Sachs stated, "We downgrade AGN from Buy to Neutral, within our Attractive coverage view; our estimates...